Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
- Conditions
- Carcinoma of Unknown Primary
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 89
- Registration Number
- NCT00873119
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸Baton Rouge Medical Center, Baton Rouge, Louisiana, United States
Phase 3 Clinical Study for the Treatment of Cold Sore
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 1727
- Registration Number
- NCT00769314
- Locations
- 🇺🇸
Radiant Research, Inc.,, Tucson, Arizona, United States
🇺🇸Dermatology Private Practice, San Fransisco, California, United States
🇺🇸Front Range Clinical Research, Wheat Ridge, Colorado, United States
Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines
- Conditions
- Anthracycline Extravasation
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT00548561
- Locations
- 🇩🇰
Aalborg Hospital South, Aalborg, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇰Herlev County Hospital, Herlev, Denmark
A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines
- Conditions
- Extravasation
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT00548704
- Locations
- 🇩🇰
Aalborg Hospital South, Aalborg, Denmark
🇩🇰Aarhus County Hospital, Aarhus, Denmark
🇩🇰Aarhus Municipality Hospital, Aarhus, Denmark
A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT00437736
- Locations
- 🇨🇭
Oncology Institute of Southern Switzerland, Hospital of Bellinzona, Bellinzona, Switzerland
🇨🇭Multidisciplinary Oncology Center, Cantonal University Hospital of Vaud, Lausanne, Switzerland
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT00435084
- Locations
- 🇬🇧
Department of Heamtology, Cardiff and Vale NHS Trust, Cardiff, United Kingdom
🇬🇧Department of Heamtology, Leeds General Infirmary, Leeds, United Kingdom
🇬🇧Department of Heamtology, Bart's and the London NHS Trust, London, United Kingdom
A Study to Assess APO866 for the Treatment of Advanced Melanoma
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2015-09-29
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT00432107
- Locations
- 🇦🇹
Department of Dermatology, Medical University Graz, Graz, Austria
🇫🇷Department of Dermatology, Hopital Henri Modor, Créteil, France
🇫🇷Department of Dermatologie, Hotel Dieu, Nantes, France
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT00431912
- Locations
- 🇦🇹
Department of Dermatology, Medical University Graz, Graz, Austria
🇫🇷Deapartment of Dermatology, Créteil, France
🇫🇷department of Dermatologie, Hotel Dieu, Nantes, France
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT00431340
- Locations
- 🇺🇸
Oncotherapeutics, West Hollywood, California, United States
🇺🇸Center for cancer and blood disorders, Bethesda, Maryland, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
- Conditions
- Ovarian CancerEpithelial Ovarian CancerBladder CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 80
- Registration Number
- NCT00421889
- Locations
- 🇺🇸
Gynecologic Oncology Associates, Newport Beach, California, United States
🇺🇸Research Facility, Orlando, Florida, United States
🇺🇸Hematology and Oncology Specialists, LLC, Covington, Louisiana, United States